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Abstract
Background: Lipid dysregulation is associated with several key characteristics of Alzheimer’s disease (AD), including
amyloid-β and tau neuropathology, neurodegeneration, glucose hypometabolism, as well as synaptic and
mitochondrial dysfunction. The β-site amyloid precursor protein cleavage enzyme 1 (BACE1) is associated with
increased amyloidogenesis, and has been affiliated with diabetes via its role in metabolic regulation.
Methods: The research presented herein investigates the role of hBACE1 in lipid metabolism and whether specific
brain regions show increased vulnerability to lipid dysregulation. By utilising advanced mass spectrometry
techniques, a comprehensive, quantitative lipidomics analysis was performed to investigate the phospholipid, sterol,
and fatty acid profiles of the brain from the well-known PLB4 hBACE1 knock-in mouse model of AD, which also
shows a diabetic phenotype, to provide insight into regional alterations in lipid metabolism.
Results: Results show extensive region – specific lipid alterations in the PLB4 brain compared to the wild-type, with
decreases in the phosphatidylethanolamine content of the cortex and triacylglycerol content of the hippocampus
and hypothalamus, but increases in the phosphatidylcholine, phosphatidylinositol, and diacylglycerol content of the
hippocampus. Several sterol and fatty acids were also specifically decreased in the PLB4 hippocampus.
Conclusion: Collectively, the lipid alterations observed in the PLB4 hBACE1 knock-in AD mouse model highlights
the regional vulnerability of the brain, in particular the hippocampus and hypothalamus, to lipid dysregulation,
hence supports the premise that metabolic abnormalities have a central role in both AD and diabetes.
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Background
The brain contains the second highest lipid content of all
the organs in the human body [1], where the compositional
diversity of lipids and the wide ranging lipid-lipid and lipid-
protein interactions have been associated with various func-
tions ranging from axonal regeneration [2] and synaptogen-
esis [3] to synaptic plasticity [4]. At a structural level,
phospholipids (with their varied fatty acid tails) and sterols
within the bilayer of cell membranes form lipid rafts, which
are specialised, highly structured regions that act as a mi-
crodomain for the regulation of specific transmembrane
proteins, such as the amyloid precursor protein (APP), and
give rise to lateral inhomogeneity within the phospholipid
bilayer [5].
Spatial and temporal lipid homeostasis is a tightly reg-
ulated process, and increasing evidence for aberrant lipid
metabolism due to the dysregulation of homeostatic
mechanisms has been linked to metabolic diseases, such
as diabetes [6], the lysomal storage disorder Niemann–
Pick disease type C [7], as well as neurological disorders
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including major depression, bipolar disorder [8], schizo-
phrenia [9], and a range of neurodegenerative disorders
including Parkinson’s disease [10], dementia with Lewy
bodies [11], and Alzheimer’s disease (AD); the focus of
the research presented herein.
Lipids, and their associated fatty acids, play a key role
in energy metabolism under glucose hypometabolism
circumstances, as associated within the AD brain, where
the compensatory shift to alternative energy substrates,
such as ketone bodies, are thought to be derived from
the beta-oxidation catabolism of fatty acids from neutral
lipids and structural lipids [12].
The role of lipid abnormalities in the pathogenesis of
AD is emphasised via the association of genes involved
in lipid transport, processing, and metabolism, such as
the ε4 allele of apolipoprotein E (APOE), which is the
strongest genetic risk factor for both sporadic early- and
late-onset AD [13]. The APOE gene encodes the major
cholesterol transporter protein that shuttles cholesterol,
as well as other lipids, between cells in an isoform-
dependent manner [14]. The APOE protein is expressed
in the periphery and the central nervous system (CNS),
predominantly in astrocytes and microglia, but also in
neurons under stress conditions [15], but interestingly
APOE does not appear to cross the blood-brain-barrier
(BBB), so the peripheral and CNS pools of the protein
are considered to be independent of each other [16].
However recent studies suggest that different APOE sta-
tuses can promote disease through different mecha-
nisms, dependent upon a leaky blood-brain barrier [17].
The importance of understanding and delineating the
mechanisms contributing to aberrant lipid homeostasis
in AD is highlighted by research suggesting the use of
lipid biomarkers to distinguish between mild cognitive
impairment (MCI) and AD [18–20], but further research
is needed to gain a more detailed understanding of the
biochemical and mechanistic alterations associated with
the lipid dysregulation observed in AD.
The recent PLB4 transgenic AD mouse model, based
upon the targeted neuronal knock-in of human BACE1
(hBACE1) on an endogenous mouse BACE1 back-
ground, recapitulates an ‘AD-like’ phenotype with age-
dependent Aβ accumulation, cognitive deficits and cere-
bral hypometabolism, as well as a diabetic phenotype
[21]. The role of BACE1 as the rate-limiting step of
Aβ40/42 production [22], together with research showing
increased protein levels and enzymatic activity of BACE1
in AD [23] make it an appealing therapeutic target [24].
However, BACE1 has many physiological roles, for ex-
ample in metabolism [25], the regulation of astrogenesis
and neurogenesis via Notch signalling [26], myelination
[27], and synaptic function [28], which complicates the
potential for inhibiting the BACE1 enzyme, and empha-
sises the need for further research into the role of
BACE1. Previous research indicates that APP may be
present in two cellular pools – one associated with lipid
rafts, which preferentially favours the amyloidogenic
cleavage by BACE1 (β-secretase) and γ-secretase, produ-
cing Aβ40/42, the other in non-raft regions, where it is
cleaved by α-secretase in the non-amyloidogenic path-
way [29]. Therefore, lipid dysregulation and alterations
in the cell membrane composition coupled with in-
creased BACE1 activity could contribute to the increased
deposition of Aβ40/42 within the brain. Insight into the
specific lipid groups influenced by BACE1 would thus
provide a mechanistic understanding of lipid alterations
that may be linked to AD-relevant phenotypes. Studies
by Plucińska et al. previously explored the global
phospholipid profile of the PLB4 forebrain and plasma
in the context of diabetes to show that PE and PS were
predominantly increased in the forebrain and plasma
samples of the PLB4 mouse model compared to the wild
type (PLBWT) [25].
This study applies a range of combinatory mass spec-
trometry techniques to characterise the key alterations
in lipid profiles associated with the neuronal hBACE1
knock-in. The phospholipid, sterol, and fatty acid con-
tent of the cortex, hippocampus, and hypothalamus of
the PLB4 mouse brain was analysed to gain insight into
the downstream effects of the hBACE1 expression, and
furthermore to investigate whether the PLB4 mouse
brain shows regional vulnerability to lipid dysregulation.
Methods
The aim of this study was to investigates the role of
hBACE1 in lipid metabolism and whether specific brain
regions show increased vulnerability to lipid dysregula-
tion. By utilising advanced mass spectrometry tech-
niques, this study presents a comprehensive, quantitative
lipidomics analysis of the phospholipid, sterol, and fatty
acid profiles of the brain from the well-known PLB4
hBACE1 knock-in mouse model of AD, which also
shows a diabetic phenotype, to provide insight into re-
gional alterations in lipid metabolism.
PLB4 hBACE1 knock-in mouse model
The PLB4 hBACE1 mouse model was generated by the
targeted knock-in of a single copy of the human bace1
(hbace1) cDNA construct, on an unaltered endogenous
bace1 +/+ background in C57BL/6 J blastocytes, as de-
tailed in Plucińska et al. [21]. The gene expression was
controlled by the mouse CaMKIIα promoter, cloned into
the HPRT locus, to ensure a neuron- and forebrain-
specific expression of the transgene. PLBWT control mice
were generated via the same knock-in technique [30].
All animals were housed and tested in accordance with
European (European Directive on the protection of ani-
mals used for scientific purposes; 2010/63/EU) and UK
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Home Office regulations, experiments were approved by
the University Ethics Board and performed in accord-
ance with the Animal (Scientific Procedures) Act 1986.
Mice were bred at Charles River UK and shipped to fa-
cilities at the University of Aberdeen at least one week
prior to tissue harvest. Animals were housed with ad
libitum access to water and food, with a circadian regime
of 12 h.
The hBACE1 expression profile in PLB4 mice was
confirmed by Southern blot, western blot, and immuno-
histochemical analysis [21], with no difference in expres-
sion detected between males and females. An AD-
relevant phenotype was the most pronounced at 6
months of age in the PLB4 mice, displaying several
memory impairments, as well as both intra- and extra-
cellular accumulation of amyloid-β throughout the fore-
brain, accompanied by the corresponding reduction of
full-length APP in the PLB4 brain (− 29% relative to
PLBWT) [21, 30].
Lipid extraction
The cortex, hippocampus, and hypothalamus were sub-
dissected on ice from PLBWT controls and PLB4 mouse
brains (n = 6; male; age: 6 months) and snap frozen in li-
quid nitrogen. Lipid extractions (all solvents used were
of HPLC grade from Sigma/Aldrich, Dorset, UK) were
performed on weighed amounts of tissue at room
temperature, according to the methodology of Bligh and
Dyer [31]; the tissue was homogenised in a 1 mL glass
Dounce homogeniser in methanol, transferred to a glass
vial, and chloroform was added to give a 1:2 (v/v) ratio
of chloroform:methanol. At the point of lipid extraction,
~ 10 μL (normalised to the amount of tissue) of the in-
ternal standard, SPLASH® LIPIDOMIX® Mass Spec
Standard (suspended 1000 μL) (Avanti Polar Lipids:
330707, AL, USA), was added to each sample for nor-
malisation, and the samples were then mixed on a
shaker (Hawksley London: 1287) for 15 min at room
temperature. Chloroform and ddH2O were added to give
a final chloroform:methanol:ddH2O ratio of 2:2:1 (v/v),
and the samples were centrifuged at 1000 g for 5 min at
room temperature. The lower phase was transferred to a
new glass vial and dried under nitrogen stored at 4 °C
until subsequent lipid analysis.
Sterol analysis
Dried lipid extracts from above were reconstituted in di-
chloromethane (~ 20 μL) and analysed by gas chromatog-
raphy - mass spectrometry (GC-MS) for identification of
sterols using a 6890 GC 5973N MSD system and 7683
Series Injector, Agilent Technologies, with a ZB-50 col-
umn (15M× 32mm ID × 0.5mm thickness, Phenomenex,
Cheshire, UK), with 1 μL splitless injection, and a GC
temperature programme of 100 °C for 1min, increase in
gradient up to 200 °C at 8 °C/ min, 200 °C for 2min, in-
crease in gradient up to 300 °C at 3 °C/ min, and 300 °C
for 15min. Sterols were identified by comparison of reten-
tion time and fragmentation pattern, and normalised to
D7-cholesterol as the internal standard, derived from the
previously added SPLASH® LIPIDOMIX® Mass Spec
Standard (Avanti Polar Lipids: 330707).
Total fatty acid analysis
Fatty acids within the lipid extracts were transmethy-
lated to fatty acid methyl esters (FAMEs) by esterifica-
tion for analysis by GC-MS. The dried lipid extract was
transmethylated with an 8% solution of HCl in metha-
nol/water (85:15, v/v) and toluene, and incubated over-
night at 45 °C, following which the methanol was
evaporated, samples dried using a Savant™ SPD121P
SpeedVac™ Concentrator (Thermo Fisher Scientific), and
hexane was added, making the solution biphasic. The
hexane layer was extracted and transferred to a new
glass vial and dried under nitrogen. The dried sample
was reconstituted in dichloromethane and analysed by
GC-MS using a 6890 GC 5973 N MSD system and 7683
Series Injector, Agilent Technologies, with a ZB-5 col-
umn (30M × 25mm × 25mm, Phenomenex), with 1 μL
splitless injection, and a GC temperature programme of
70 °C for 10 min, increase in temperature gradient up to
220 °C at 5 °C/min, and 220 °C for 15 min. FAMEs were
identified by comparison of retention time and fragmen-
tation pattern, and normalised to the C15:0 as the in-
ternal standard, derived from the previously added SPLA
SH® LIPIDOMIX® Mass Spec Standard (Avanti Polar
Lipids: 330707).
Phospholipid analysis
Phospholipids were analysed by electrospray ionisation -
tandem mass spectrometry (ESI-MS/MS) using the
Absceix 4000 QTrap, a triple quadrupole mass spec-
trometer with a nanoelectrospray source. The dried lipid
extracts were reconstituted in 1:2 (v/v) chloroform:
methanol and 6:7:2 (v/v) acetonitrile:isopropanol:water,
delivered via a nanomate, and analysed in positive and
negative ion modes using a capillary voltage of 1.25 kV.
Tandem mass spectra scanning (daughter, precursor,
and neutral loss scans) were performed using nitrogen
as the collision gas, with collision energies between 35
and 90 V. Assignment of phospholipid species was based
upon a combination of survey, daughter, precursor and
neutral loss scans; the phospholipid peaks identified
from the tandem MS/MS methodologies were identified
and verified using the LIPID MAPS Lipidomics Gateway
(http://www.lipidmaps.org). Each phospholipid class was
normalised to the corresponding internal standard from
the SPLASH® LIPIDOMIX® Mass Spec Standard (Avanti
Polar Lipids).
Dey et al. Lipids in Health and Disease          (2020) 19:201 Page 3 of 17
Statistical analysis
Following normalisation of ESI-MS/MS and GC-MS data
to the corresponding internal standard, statistical analysis
was performed on GraphPad Prism (version 7.00 software,
La Jolla California USA) using an unpaired, two-tailed Stu-
dent’s T-test with Welch’s correction or Wilcoxon signed-
rank test to determine statistically significant differences be-
tween PLBWT and PLB4 lipid species and brain regions.
Fig. 1 Sterol analysis of the PLBWT and PLB4 brain. The relative abundance of each sterol identified in the cortex (A), hippocampus (B), and
hypothalamus (C) was normalised to D7-cholesterol as the internal standard. Annotation of the major sterol species were identified from MS
daughter ion fragmentation scans. Data represented as average ± S.E.M (n = 6). The normalised abundance (arbitrary units) refers to the
normalised total ion count for individual molecular species. An unpaired, two-tailed Student’s t-test with Welch’s correction was performed to
determine statistically significant differences between PLBWT and PLB4 data. * P ≤ 0.05, ** P ≤ 0.01. Cortex: all p≥ 0.05; hippocampus:
dehydrocholesterol P = 0.0113, didehydrocholesterol P = 0.0099, cholesterol P = 0.0151; hypothalamus: cholesterol P = 0.0326
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Results
Sterol alterations in the PLB4 brain
The analysis of the PLBWT and PLB4 brain regions by
gas chromatography - mass spectrometry (GC-MS) en-
abled the detection and identification of several up-
stream components within the cholesterol biosynthesis
pathway. The abundance of the respective sterols within
the cortex, hippocampus, and hypothalamus was deter-
mined using GC-MS, which, coupled with the MS frag-
mentation scan allowed identification of all of the sterol
species detected. Normalisation of the respective individ-
ual sterol total ion count data to that of D7 cholesterol
Fig. 2 Analysis of the fatty acid species in the PLBWT and PLB4 brain. The relative abundance of each fatty acid methyl ester (FAME) identified in
the cortex (A), hippocampus (B), and hypothalamus (C) was normalised to C15:0 as the internal standard. Annotation of the major FAME species
were identified from MS daughter ion fragmentation scans. Data represented as average ± S.E.M (n = 6). The normalised abundance (arbitrary
units) refers to the normalised total ion count for individual molecular species. An unpaired, two-tailed Student’s t-test with Welch’s correction
was performed to determine statistically significant differences between PLBWT and PLB4 data. * P ≤ 0.05, ** P≤ 0.01; hippocampus FAMEs - C16:1
P = 0.0325, C16:0 P = 0.0112, C18:0 P = 0.0204, C20:3 n-6 P = 0.0060
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Fig. 3 (See legend on next page.)
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within the internal standard (added at the point of lipid
extraction) allowed a quantitative comparison between
the PLBWT and PLB4 samples (Fig. 1). The general trend
observed throughout the sterol analysis was a decrease
in all of the sterol species in the PLB4 brain regions
compared to the PLBWT controls. While the cortex (Fig.
1A) did not show any significant decrease in any particu-
lar sterol species, statistical decreases in the cholesterol
levels were observed in the PLB4 hippocampus and
hypothalamus brain regions. The majority of the sterol
alterations were in the PLB4 hippocampus (Fig. 1B), with
statistically significant decreases seen in dehydrocholes-
terol (by 3.3-fold, P = 0.0133), didehydrocholesterol (by
7.8-fold, P = 0.0099), and cholesterol (by 5.9-fold P =
0.0151) compared to the PLBWT hippocampus. The
most prominent change in the hypothalamus samples
was a statistically significant decrease by 2.0-fold (P =
0.0326) in the cholesterol content of the PLB4 hypothal-
amus compared to the PLBWT hypothalamus (Fig. 1C).
Fatty acid alterations in the PLB4 brain
Fatty acids within the lipid extracts were transmethy-
lated to fatty acid methyl esters (FAMEs), which were
then analysed by GC-MS. The detection and identifica-
tion of saturated and unsaturated fatty acids was per-
formed by utilising a combination of the GC retention
time and the MS fragmentation pattern comparing with
standards. Normalisation of the respective FAME total
ion count data to that of C15:0 within the internal
standard (added at the point of lipid extraction) allowed
a quantitative comparison between the PLBWT and PLB4
samples derived from the different brain regions
(Fig. 2A-C). Although a large degree of biological vari-
ability was observed between the replicate samples, the
highest number of alterations were observed within the
hippocampus (Fig. 2B), which showed statistically signifi-
cant decreases in C16:1 (palmitoleic acid) by 4.2-fold
(P = 0.0325), C16:0 (palmitic acid) by 4.0-fold (P =
0.0112), C18:0 (stearic acid) by 3.5-fold (P = 0.0204), and
C20:3 n-6 (dihomo-γ-linoleic acid) by 4.6-fold (P =
0.0060) in the PLB4 hippocampus compared to the
PLBWT hippocampus. The ratio of saturated to unsatur-
ated FAMEs within each brain region was also calculated
from the normalised GC-MS data to investigate whether
the alterations observed in the PLB4 brain preferentially
influenced either type of FAME (Supplementary Fig. S1),
but no statistically significant alterations were observed.
Phospholipid alterations in the PLB4 brain
ESI-MS/MS was used to determine the phospholipid
profile of the cortex, hippocampus, and hypothalamus of
the PLB4 hBACE1 knock-in murine model of AD. Ana-
lysis of phosphatidylglycerols (PG), phosphatidylethanol-
amines (PE, including lyso-phosphatidylethanolamines
(LPE)) and sphingomyelins (SM) are shown in Fig. 3,
phosphatidylcholines (PC, including lyso-phosphatidyl-
cholines (LPC)), diacylglycerols (DG) and triacylglycerols
(TG) in Fig. 4, phosphatidylinositols (PI, including lyso-
phosphatidylinositols LPI)), phosphatidylserines (PS),
phosphatidic acids (PA), ceramides (Cer) and other
sphingolipids in Fig. 5, and the collective phospholipid
profiles in Fig. 6. Results showed statistically significant
alterations in PE, PC, PI, TG, DG, PS, Cer, SM, PG, and
PA, listed in order of abundance of changes, the majority
of which were observed in the PLB4 hippocampus,
followed by the hypothalamus, and a few alterations
were found in the cortex. A summary of the significant
alterations between individual phospholipid species in
the PLBWT and PLB4 cortex, hippocampus, and hypo-
thalamus samples, are listed in Supplementary Table 1.
Statistically significant alterations were observed in 30
different PE species including plasmalogen PE in the
PLB4 hippocampus, and the PLB4 cortex, but only 5 PE
species (4 of which were plasmalogen) in the PLB4
hypothalamus – compared to PLBWT control (Fig. 3).
The observed changes within the plasmalogen PEs were
the largest in the hippocampus, the changes are very spe-
cific depending upon acyl chain length, which may imply
specific lipids may have specific roles within different
sub-regions of the hippocampus. The overall PE content
showed a statistically significant decrease by 1.5-fold
(P = 0.0189) in the PLB4 cortex compared to PLBWT, a
decrease in PE content was also observed in the PLB4
hippocampus, and an increase in the PLB4 hypothal-
amus, but no statistical significance was observed (Fig.
6). While some individual PC species were increased in
the PLB4 cortex (1 alteration) and hippocampus (12 al-
terations, predominantly increased), the PLB4 hypothal-
amus showed the biggest changes, with a total of 22
altered PC species – 2 increases and 20 decreases (Fig.4).
The total PC content of the PLB4 hippocampus showed
a statistically significant increase by 1.5-fold (P = 0.0469)
compared to the PLBWT hippocampus (Fig. 6).
Several alterations in PI species were detected across
all three brain regions (Fig. 5): the PLB4 cortex showed
(See figure on previous page.)
Fig. 3 Phospholipid analysis of the PG, PE, and SM content of the PLBWT and PLB4 brain. Analysis of the phosphatidylglycerols (PG),
phosphatidylethanolamines (PE), and sphingomyelins (SM) in the PLBWT and PLB4 cortex, hippocampus, and hypothalamus. Each phospholipid
class was normalised to its corresponding internal standard. The relative intensity (cps) refers to the normalised total ion count (TIC) for the
individual molecular species. Data represented as an average of n = 6. An unpaired, two-tailed Student’s t-test with Welch’s correction was
performed to determine statistically significant differences between PLBWT and PLB4 data; * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001
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Fig. 4 (See legend on next page.)
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the biggest changes, with altered levels of 9 PI species,
followed by the PLB4 hypothalamus with 5 alterations,
and the PLB4 hippocampus with 4 alterations. Whilst
LPI (18:0) showed a consistent decrease across all three
PLB4 brain regions, PI (36:4) was decreased in both the
PLB4 cortex and hippocampus, but increased in the
PLB4 hypothalamus – compared to PLBWT. Total PI
levels were slightly decreased in both the PLB4 cortex
and hippocampus, but showed a statistically significant
increase in the PLB4 hypothalamus by 1.5-fold (P =
0.0444) compared to PLBWT (Fig. 6). Many TG species
were decreased in the PLB4 hypothalamus (6 changes),
PLB4 cortex (4 changes) and PLB4 hippocampus (3
changes; Fig. 4). The most pronounced alterations were
observed in TG (58:12), TG (62:14), and TG (66:18) –
which were all depleted in the PLB4 hypothalamus com-
pared to the PLBWT hypothalamus. The total TG con-
tent showed a statistically significant decrease in the
PLB4 hippocampus, by 1.5-fold (P = 0.0009), as well as
in the PLB4 hypothalamus by 3.1-fold (P = 0.0090) –
compared to PLBWT (Fig. 6). Across the panel of 7 DG
species identified (Fig. 4), many showed an increase in
both the PLB4 cortex and hippocampus, with statistically
significant increases observed in 3 DG species in the
PLB4 cortex and 1 DG species in the PLB4 hippocam-
pus. However, the PLB4 hypothalamus displayed the op-
posite trend, showing decreased levels of several DG
species. In particular, the most prominent change was
observed in DG (42:10), which was completely depleted
in the PLB4 hypothalamus compared to the PLBWT
hypothalamus, but increased in the PLB4 cortex and
hippocampus. Overall, the total DG levels showed a sta-
tistically significant increase in the PLB4 hippocampus
by 1.4-fold (P = 0.0378) compared to PLBWT (Fig. 6).
The majority of the PS alterations were observed in
the PLB4 hypothalamus (Fig. 5), where 4 PS species
showed statistically significant decreases compared to
PLBWT, with one increase observed in the PLB4 hippo-
campus, and no statistically significant changes found in
the cortex. Whilst total PS levels showed a decrease
across all three PLB4 brain regions, no statistically sig-
nificant alterations were observed (Fig. 6). Some statisti-
cally significant alterations were observed in the Cer
species in the PLB4 hippocampus (2 changes) and hypo-
thalamus (3 changes), but none in the cortex (Fig. 5). No
statistically significant alterations were detected in the
total Cer content of either the PLB4 cortex,
hippocampus, or cerebellum (Fig. 6). Of the 7 SM spe-
cies identified (Fig. 3), only 1 was decreased in the PLB4
cortex, while 1 was increased in the PLB4 hypothalamus,
compared to PLBWT. The total SM content showed a
slight decrease in both the PLB4 cortex and hippocam-
pus, and a slight increase in the PLB4 hypothalamus, but
no statistically significant differences were detected (Fig.
6). A modest increase in the major monogalactosylcera-
mides, identified as HexCer (d36:2), in both the hypo-
thalamus and hippocampus (Fig. 5) were observed.
Three different gangliosides were identified (Fig. 5), but
their levels did not seem significantly altered in any of
the brain regions of the mouse PLB4 model, compared
to wild-type.
Whilst several PG species were detected across the
PLBWT and PLB4 samples (Fig. 3), only PG (38:0)
showed a statistically significant increase in the PLB4
cortex compared to the PLBWT cortex, and no statisti-
cally significant changes were detected in the total PG
content in any of the three brain regions (Fig. 6). No sta-
tistically significant alterations were observed in the PA
levels between the PLBWT and PLB4 brain regions
(Figs. 5 and 6).
Discussion
Lipidomics is a powerful analytical platform, which al-
lows extensive analysis of the multifaceted lipidome. The
combinatory use of GC-MS and ESI-MS/MS enabled the
detection, identification, and analysis of a range of ste-
rols, fatty acids, and phospholipids in brain regions rele-
vant to the pathogenesis of AD, highlighting alterations
in specific lipids. This comprehensive quantitative lipido-
mics analysis identified a total of forty-nine lipid alter-
ations in the cortex, sixty in the hippocampus, and fifty-
one in the hypothalamus of the PLB4 mouse brain, as
summarised in Table 1, thus providing detailed insight
into the consequences of the targeted neuronal knock-in
of hBACE1 upon phospholipid, sterol, and fatty acid
levels within the three brain regions. In addition to de-
tecting overall changes in lipid classes, the lipidomics ap-
proach identified specific lipid species that are altered
within the corresponding groups, allowing for a thor-
ough, quantitative comparison between the PLBWT and
PLB4 mouse brain regions. The results suggest disrup-
tions in key lipid metabolism pathways – furthermore,
these disruptions may be highly localised, thus support-
ing the notion of selective vulnerability of certain brain
(See figure on previous page.)
Fig. 4 Phospholipid analysis of the PC, DG, and TG content of the PLBWT and PLB4 brain. Analysis of the phosphatidylcholines (PC), diacylglycerols
(DG), and triacylglycerols (TG) in the PLBWT and PLB4 cortex, hippocampus, and hypothalamus. Each phospholipid class was normalised to its
corresponding internal standard. The relative intensity (cps) refers to the normalised total ion count (TIC) for the individual molecular species.
Data represented as an average of n = 6. An unpaired, two-tailed Student’s t-test with Welch’s correction was performed to determine statistically
significant differences between PLBWT and PLB4 data; * P≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 (white asterisks used only for visibility purposes)
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regions to AD pathogenesis during the progression of
the disease.
The PLB4 model displays several disease relevant phe-
notypes, and recapitulates the early stages of AD due to
the increased production and aggregation of Aβ40/42,
without the formation of end-stage Aβ plaques [32].
Therefore, the model offers an opportunity to observe
early alterations within the murine brain that arise due
to low level expression of the hBACE1 enzyme and the
resultant increase in Aβ production. In the human AD
brain, tau pathology, rather than Aβ pathology, is
strongly associated with disease progression, and neuro-
pathological studies show that the burden of tau neuro-
fibrillary tangles, but not Aβ pathology, correlates with
the degree of cognitive impairment [33, 34]. Notably
however, the PLB4 hBACE1 AD mouse model displays
memory impairments at 6 months of age, despite the
lack of overt tau pathology within the brain [21], there-
fore suggesting that the hBACE1 knock-in and metabolic
dysfunction may have a role in influencing the cognitive
deficits observed. Impairments in cerebral metabolism
have been linked to cognitive decline in AD [35, 36],
thus, the role of BACE1 in metabolic regulation and the
diabetic phenotype observed in the PLB4 hBACE1
knock-in mouse model may contribute to memory im-
pairment. Cholesterol-based microdomains of the
phospholipid bilayer at synapses influence several essen-
tial aspects of neurotransmission, ranging from regula-
tion of synaptic protein activity, to vesicle fusion, as well
as synapse formation and stability [37, 38]. Conse-
quently, a potential cause for the cognitive symptoms
seen in the PLB4 hBACE1 knock-in mice may be the al-
terations in cholesterol regulation within the brain, as
highlighted by the results from the lipidomics analysis.
Additionally, analysis of the phospholipids within the
PLB4 hippocampus revealed an increase in the total PC
content, which is a precursor and suggested reservoir for
choline within the cholinergic system [39]. Cholinergic
deficits in the AD brain are strongly linked to cognitive
impairment, and thus, the alterations in the PC content
of the PLB4 hippocampus may suggest underlying modi-
fications in cholinergic neurotransmission within the
brain.
Analysis of the fatty acid profile of the PLB4 hBACE1
knock-in mouse brain highlighted many alterations
within the hippocampus, thus suggesting a potential role
for BACE1 in the pathological mechanisms influencing
fatty acid metabolism in AD. Analysis of the phospho-
lipid profiles in the PLB4 brain indicate alterations in
many PE species, which is the second most abundant
phospholipid in the mammalian cell [40], and is directly
associated with mitochondrial membrane dynamics, sta-
bility and function [40]. PE metabolism is linked with PS
metabolism via the PS decarboxylase pathway [40], and
thus may indicate an interconnected mechanism for the
altered PS levels observed in the PLB4 hippocampus.
The metabolism of PI, which showed many alterations
in the PLB4 brain, is linked with a multitude of signal-
ling pathways, including protein kinase C (PKC) activa-
tion, and calcium signalling, with implications upon cell
motility, adhesion, and survival [41], as well several key
aspects of neurotransmission [42], hence the decreased
levels of PI within the PLB4 brain could have widespread
downstream effects.
An important influence of lipid dysregulation observed
within the various brain regions in the AD-like mouse
model is upon neurotransmission via lipid-protein inter-
actions at synapses. Lipids, both within the cell mem-
brane and those involved in signalling cascades, play an
essential role to regulate the activity of synaptic proteins,
as well as the coordination of exo- and endocytotic fu-
sion of synaptic vesicles. In AD, synaptic dysfunction has
been associated with altered post-synaptic density scaf-
folds and glutamatergic neurotransmission, which in
turn have been linked to alterations in the lipid compos-
ition of subsynaptic protein domains via membrane lipid
rafts [28–30].
The significant reduction in the neutral lipids in the
hypothalamus does suggest that they may be utilised as
an energy source, i.e. fatty acid beta-oxidation, which
would fit well with the hypothesis that a reduction in
glycolysis is associated with ageing of the brain and, in
extreme cases, the catabolism of structural proteins
could result in irreversible damage, leading to several
types of dementia including AD, as they are involved in
several complex signalling networks, including PKC acti-
vation and calcium-mediated vesicle fusion [43], as well
as synaptic modulation via glutamate receptors [44].
Furthermore, a recent study by Wood et al. reported ele-
vated DG levels in both the frontal cortex and plasma
samples of subjects with MCI, and proposed that the ac-
cumulation of DG, as observed here in the cortex and
(See figure on previous page.)
Fig. 5 Phospholipid analysis of the PI, PS, PA and Cer content of the PLBWT and PLB4 brain. Analysis of phosphatidylinositols (PI),
phosphatidylserines (PS), phosphatidic acids (PA) and ceramides (Cer) in the PLBWT and PLB4 cortex, hippocampus, and hypothalamus. Each
phospholipid class was normalised to its corresponding internal standard. The relative intensity (cps) refers to the normalised total ion count (TIC)
for the individual molecular species. Data represented as an average of n = 6. An unpaired, two-tailed Student’s t-test with Welch’s correction was
performed to determine statistically significant differences between PLBWT and PLB4 data; * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 (white asterisks
used only for visibility purposes)
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hippocampus, occurs early during the pathophysiological
progression of AD [45]. Additionally, increased cellular
DG content has also been linked to insulin resistance via
the activation of PKC, which consequently influences
glycogen synthesis [32].
Several phospholipid groups in the forebrain and
plasma of PLB4 hBACE1 knock-in mice were previously
assessed by the Folch lipid extraction technique and LC/
MS [25] – interestingly, many lipid classes were predom-
inantly increased in the PLB4 forebrain. Comparatively,
the results from this study, which used the Bligh and
Dyer lipid extraction methodology [31] and ESI/MS-MS
to analyse brain region-specific phospholipid alterations
showed some similarities. However, these results pre-
dominantly showed decreased levels of several minor,
but important, phospholipid species across the cortex,
hippocampus, and hypothalamus of the PLB4 brain com-
pared to PLBWT. Possible reasons for the variations ob-
served could be due to the analysis of the lipid content of
the entire PLB4 forebrain in the study by Plucińska et al.
[25] compared to that of specific PLB4 brain regions in
the current study, as well as differences in the lipid extrac-
tion technique and quantitative lipidomics analyses.
A similar comparative lipidomics study was performed by
Chan et al. [46], which investigated the lipid profile of the
forebrain in three commonly used familial AD murine
models: the PSEN1M146V (PS1) model [47], the
APPK670N,M671L Swedish mutant (APPSwe) [48], and the
PS1-APP double transgenic model [49], between the ages
of 9–11.5months, using the Bligh and Dyer lipid extrac-
tion method, and LC/MS. As with our analysis, the PS1
single transgenic AD mouse model showed significant de-
creases in the PS and PI content of the forebrain, as did
the APPSwe mouse model, which additionally displayed an
overall increase in PC levels. Many of these changes were
also seen in the PS1-APP mouse forebrain, and the au-
thors proposed a potential synergistic effect of the two
transgenes. The study by Chan et al. also compared the
lipid profiles of the prefrontal cortex, entorhinal cortex,
and cerebellum from human post mortem late-onset AD
cases, noting that, on average, the entorhinal cortex exhib-
ited higher levels of neuropathology than the prefrontal
cortex. Results from their analysis showed that the pre-
frontal cortex and entorhinal cortex lipid profiles showed
abundant alterations, such as decreased levels of PE, and
increased levels of Cer, DG, and SM, amongst others
sphingolipids, which was also observe in this study.
While there are numerous caveats to comparisons be-
tween various transgenic AD mouse models, including
even the different WT background from which the trans-
genic murine lines are derived, and further to post mor-
tem human AD brain tissue, the results from the hBACE1
knock-in mouse model of AD supports the concept of
brain region – specific alterations in lipid metabolism.
This comprehensive lipidomics analysis indicates dysregu-
lation of various lipid metabolism pathways, with brain re-
gion specificity, and furthermore could suggest the
pathological dysregulation of key enzymes integral to the
regulation of lipid homeostasis within the brain. Whilst
further investigations need to be undertaken to assess
whether the lipid alterations we observed are cause or
consequence of the ‘AD-like’ and diabetic phenotype of
the PLB4 hBACE1 knock-in mouse model, the findings
highlight potential lipid groups that warrant further inves-
tigations. The importance of delineating the mechanisms
contributing to aberrant lipid homeostasis in AD is
highlighted by research suggesting the use of lipid bio-
markers to distinguish between MCI and AD [18–20].
The results here, alongside several other lipidomics
studies, show the importance of assessing brain-region
specific lipid alterations, and lays the foundation for fur-
ther investigations into changes within specific lipid me-
tabolism pathways. In particular, it would be interesting
to explore the alterations in lipid metabolism pathways
at the protein level, and whether the inhibition of
BACE1 reverted the lipid alterations observed towards a
WT profile. Additionally, considering the region-specific
variations seen in lipid classes and specific lipid species
within the PLB4 brain, investigating the metabolic inter-
dependence of different cell types within the brain re-
gions could also provide valuable insight.
Recent advances in mass spectrometry techniques,
such as imaging have for the first time allowed direct
probing of brain sections/regions. These have clearly
highlighted specific alterations of a range of lipids in AD
brains and plaques [50–52]. However, advances in im-
proving the absolute resolution of the brain area that
can be queried will allow small sub-regions of the brains
to be analyzed, One of the drawbacks of these direct
methods is ion suppression by those species that ionize
(See figure on previous page.)
Fig. 6 Phospholipid profiles of the PLBWT and PLB4 cortex, hippocampus, and hypothalamus. Each lipid class (sum of all species) is represented as
an average percentage (± SEM) of the corresponding PLBWT class, n = 6. A Wilcoxon signed-rank test was performed to determine statistically
significant differences between PLBWT and PLB4 data, where * denotes P ≤ 0.05. Cortex: PE PLBWT vs. PLB4: P = 0.0313; DG PLBWT vs. PLB4: P =
0.0313; TG PLBWT vs. PLB4: p = 0.0313. Hippocampus: PC PLBWT vs. PLB4: P = 0.0313; TG PLBWT vs. PLB4: P = 0.0313. Hypothalamus: TG PLBWT vs.
PLB4: P = 0.0313. Abbreviations: PE – phosphatidylethanolamine, PS – phosphatidylserine, PI – phosphatidylinositol, PC – phosphatidylcholine, CER
– ceramide, DG – diacylglycerol, TG – triacylglycerol, PA – phosphatidic acid, SM – sphingomyelin, PG – phosphatidylglycerol
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Table 1 Summary of the lipid alterations in the PLB4 cortex, hippocampus, and hypothalamus. Lipid species listed by class showing
the most the statistically significant alterations in the PLB4 brain compared to PLBWT. An unpaired, two-tailed Student’s T-test with
Welch’s correction was performed to determine statistically significant differences between PLBWT and PLB4 lipid species and
brain regions: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. Abbreviations: PE – phosphatidylethanolamine, PC – phosphatidylcholine, PI
– phosphatidylinositol, TG – triacylglycerol, DG – diacylglycerol, PS – phosphatidylserine, Cer – ceramide, SM – sphingomyelin,
PG – phosphatidylglycerol
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well, i.e. phosphatidylcholine, over neutral lipids.
Coupled with a lack of the ability of spiking internal
standards, means that absolute quantification is as yet
not possible.
Study strengths and limitations
The strengths of this study are that the results show ex-
tensive brain region-specific phospholipid alterations, as
well as several sterol and fatty acid changes in the PLB4
brain, which indicate modifications in lipid homeostasis
and likely several lipid metabolic pathways relevant to
the pathogenesis of AD. This PLB4 mouse model, in
conjunction with potential therapies could allow a read-
out both from behaviours, but also from readdressing
the lipid “miss-use”, i.e. catabolism of lipids by an “AD-
like” brain. However, the limitations of any type of lipi-
domic or metabolomic study of this nature, is the fact
that it is only a model, and the data obtained is only a
snap shot for this type of analysis, telling us nothing
about the actual rate/flux of certain metabolic functions/
pathways.
Conclusion
In conclusion, several significant brain-region specific
alterations were found within many major and minor
lipid groups in the PLB4 hBACE1 knock-in mouse
brain, many of which were observed predominantly in
the hippocampus and hypothalamus, which is in con-
cordance to the neuropathological and clinical pro-
gression of AD, and highlights the relevance of this
mouse model for AD research. Collectively, these re-
sults are consistent with the hypothesis of regional
vulnerability of the brain to lipid dysregulation, and
supports the premise that metabolic abnormalities
have an important role in both AD and diabetes,
where a carbon source usage is important for fuelling
the brain. While this study has identified important
alterations within key lipid species, further research is
needed to gain more detailed understanding of the
biochemical and mechanistic alterations associated
with the lipid dysregulation observed in AD. A future
perspective of this work is the use of this mouse
model as a way to evaluate possible therapies to re-
address the lipid dysregulation and imbalance
observed.
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